Small Cap Stocks to Watch - TWTI, IMAX, DNDN, JAVO
Winston-Salem 3/12/2008 12:46 PM GMT (TransWorldNews)
To register for the Free SmallCapReview Newsletter and automatically be entered to win a Blackberry Pearl visit http://www.smallcapreview.com/subscribe.htm
Third Wave Technologies (Nasdaq: TWTI) Closed at $7.10. Announced yesterday after market close that the company achieved all primary clinical endpoints in the clinical trial for its human papillomavirus (HPV) tests. The company expects to submit the trial results to the U.S. Food and Drug Administration for both its high-risk and 16/18 genotyping products in April. TWTI is a new Focus Stock at SmallCapReview.
Third Wave’s 14-type high-risk HPV test demonstrated a negative predictive value greater than the study’s 99% goal. Negative predictive value is the probability that there is no cervical disease in a patient with atypical or ASCUS Pap test results and negative HPV test results.
The company’s proprietary high-risk HPV test is intended to be used in combination with a Pap test to assess women 30 and over for the presence of high-risk HPV types and to guide their treatment. It is also intended to test patients with abnormal Pap results to determine whether they should be referred to colposcopy.
Texas Instruments (NYSE: TXN) DLP Cinema announced today that IMAX (Nasdaq: IMAX) Closed at $6.69 will incorporate the DLP Cinema projector solution. Under the terms of the agreement, each IMAX® Digital projection system to be deployed to commercial exhibitors around the world, scheduled to begin mid-2008, will be powered by DLP Cinema projectors. Imax is a current Focus Stock at SmallCapReview.
IMAX's highly anticipated digital projection system integrates a suite of proprietary IMAX intellectual properties with the DLP Cinema projector solution in a way that creates The IMAX® Experience in a digital format. Digital cinema installations continue to be catalyzed by the increasing release of 3D film. The 3D movie format is serving as a revenue driver for the film industry overall, and has gained a resurgence of interest by moviegoers. IMAX has been a leader in 3D content, especially since the overwhelming box office success of The Polar Express: An IMAX 3D Experience, which has grossed more than $65 million in IMAX theatres around the world since it opened in 2005. More recently, Beowulf: An IMAX 3D Experience grossed $25 million, representing a per screen average of more than $185,000.
Dendreon Corporation (Nasdaq: DNDN) Closed at $4.93. Today announced that the U.S. Food and Drug Administration (FDA) has agreed to an amended Special Protocol Assessment (SPA) for the Phase 3 IMPACT (IMmunotherapy for Prostate AdenoCarcinoma Treatment, also known as D9902B) clinical trial of PROVENGE® (sipuleucel-T), the Company's investigational active cellular immunotherapy for the treatment of advanced prostate cancer. In addition, the FDA has reconfirmed that they would accept a positive interim or final analysis from the IMPACT trial to amend the Biologics License Application (BLA) for licensure of PROVENGE.
The amended SPA accelerates the expected timing of the final IMPACT results by approximately one year while maintaining comparable powering of the study's interim and final results.
Javo Beverage Company (OTCBB: JAVO) Closed at $0.53. Announced yesterday that it will release its financial results for the fourth quarter and fiscal year ended December 31, 2007 on Monday, March 17, 2008. The management of Javo Beverage will host a conference call on the same day at 11:30 a.m. EDT to discuss the company’s financial results and achievements. Those who wish to participate in the conference call may telephone (888) 335-6674 from the U.S. or (973) 582-2845 for international callers, conference ID# 39025302 approximately 15 minutes before the call. A digital replay will be available by telephone for 30 days and may be accessed by dialing (800) 642-1687, from the U.S., or (706) 645-9291, for international callers, conference ID# 39025302.
Javo Beverage Company is an innovator and leader in the manufacture of coffee and tea-based dispensed beverages, drink mixes and flavor systems. The company has successfully commercialized a proprietary brewing technology that yields fresh brewed coffees and teas that are flavorful, concentrated and stable, with broad applications in the food service, food manufacturing and beverage industries.
editor@smallcapreview.com
www.smallcapreview.com
Email Article to a friend
|
View Profile
Visit Blogs
|
NEWS ALERTS
Receive alerts for
TWTI
to your inbox.
Sign up for TransWorldNews Alerts
TransWorldNews, Inc. and its affiliate sites disclaim all liability for information and content provided by clients and appearing within their news and press releases.
